Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

thrombocytopenia due to immune destruction - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

thrombocytopenia due to immune destruction

MONDO:0002048

Also known as:immune thrombocytopeniaauto-immune thrombocytopeniathrombocytopenia due to platelet alloimmunization

Find Clinical TrialsTrials

Overview

A general class of thrombocytopenia due to immune destruction of platelets. It includes idiopathic thrombocytopenic purpura, as well as immune destruction-related thrombocytopenias due to other reasons (e.g., AIDS, transfusion, lupus erythematosus).

Treatments1 FDA approved, newest 2025

Clinical Trials129 registered · 77 recruiting

Diagnosis

Biomarker and diagnostic research for thrombocytopenia due to immune destruction has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

1 FDA-approved treatment is available for thrombocytopenia due to immune destruction, including RILZABRUTINIB (WAYRILZ, approved 2025). An additional 3 compounds hold orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

129 clinical trials registered, 77 recruiting. Interventions under study include drug therapy, other interventions, biologic therapy, and gene therapy. Pipeline includes 6 PHASE4, 18 PHASE3, 41 PHASE2. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT06929299](https://clinicaltrials.gov/study/NCT06929299)

Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 4:52 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

Questions for Your Care Team

→What are the benefits and potential side effects of WAYRILZ for managing thrombocytopenia due to immune destruction?
→Are any of the 129 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
rituximab	rituximab	ODDIFACT SAS	2024	—	Designated
Mezagitamab	Mezagitamab	Takeda Development Center Americas, Inc.	2023	—	Designated
Humanized IgG4 monoclonal antibody against total complement component 1, subcomponent s	Humanized IgG4 monoclonal antibody against total complement component 1, subcomponent s	Recordati Rare Diseases Inc.	2018	—	Designated

Research Type	Count	% of Total
Research summaries	138	37%
Patient case studies	80	21%
Laboratory research	57	15%
Disease patterns and progression	46	12%
Clinical study results	21	6%
Testing and diagnosis research	17	5%
New treatment approaches	11	3%
Other research	5	1%

Kisho

thrombocytopenia due to immune destruction

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Medical References

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Adverse Event Profiles

Clinical Trials

Recent Publications

thrombocytopenia due to immune destruction

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Medical References

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Adverse Event Profiles

Clinical Trials

Recent Publications